Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Novartis | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Novartis

Pharma sales up 1% in the quarter, benefits from delayed Diovan generic in the U.S.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Novartis
 
4Q Revenues: $15.1 billion (+2%)

4Q Earnings: $3.0 billion (-3%)

FY Revenues: $57.9 billion (+2%)

FY Earnings: $12.5 billion (flat)

Comments: Pharmaceutical sales were $8.3 billion in the quarter, up 1%, with growth products contributing $4.8 billion or 32% of group sales, up 15%, offset by the impact of generic competition for Zometa/Aclasta and Diovan. Gilenya, Afinitor, Tasigna, Galvus, Lucentis, Xolair, the Q Family[2] and Jakavi, generated $3.3 billion in sales, or 40% of division sales, compared to 33% in 4Q12. Alcon sales were $2.7 billion in the quarter (+3%). Sandoz sales were $2.4 billion (+1%), and included U.S. generic sales of valsartan HCT and four months of Fougera sales. Vaccines and Diagnostics sales were up 4% to $655 million, driven by seasonal influenza, pre-pandemic sales including H7N9 in the U.S. and Menveo growth, partially offset by lower pediatric bulk sales due to earlier supply phasing.
Consumer Health sales grew 8% to $1.0 billion.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters